Interventional Cardiology Market size was valued at USD 19,274.6 million in 2022 and is expected to grow at a 9.0% CAGR from 2023 to 2029. Interventional cardiology is a subspeciality in the cardiology that uses specialized catheter-based techniques to diagnose and treat various heart disease like congenital heart disease, coronary artery disease, vascular disease and others. The interventional cardiology uses various imaging and diagnostic tools to diagnose cardiovascular functions such as blood flow, blood pressure in major arteries in our body. The evolution of interventional cardiology technique has eliminated the traditional open-heart surgeries. The Rapid increase in geriatric population, increasing awareness of cardiovascular drugs disease and the increase in consciousness of people to monitor cardiac health, rapid increase in chronic diseases like diabetes, cardiac makers disease among the population is expected to drive the growth of interventional cardiology market in the forecasted years. Furthermore, increasing incidence of cardiovascular disease along with the growing healthcare expenditure in medical device is expected to push the market growth in the forecasted years. In addition, the rise in tobacco consumption and the growing incidence of obesity is also expected to fuel the growth of interventional cardiology market. Several government and non-government organizations including educational institutes and key market payers, have conducted public awareness campaigns to raise the awareness regarding cardiac disease and its treatments. The advancement of technology and procedures in healthcare facility like innovative cardiovascular devices and regulatory approvals are expected to fuel the growth of interventional cardiology market in the forecasted years. However, the huge cost of interventional cardiac devices and the availability of alternative cardiac disease treatments are expected to hinder the growth of interventional cardiology market in the forecasted years. Geographically, North America region held the major market share in 2022 and is expected to dominate the global interventional cardiology market in the forecasted years.

Interventional Cardiology Market Key Developments:
In July 2021, Abbott launched its product XIENCE family of stents, which got USFDA’s approval for one month DAPT labeling for patients with high bleeding risk in US.